Loading clinical trials...

Ovarian Hyperstimulation Syndrome Using Calcium Infusion | Clinical Trials | Clareo Health

UNKNOWNNA

Ovarian Hyperstimulation Syndrome Using Calcium Infusion

Ovarian Hyper Stimulation Syndrome Using Calcium Infusion

NCT05198128•Al-Azhar University

View on ClinicalTrials.gov

Summary

the incidence of OHSS and clinical outcomes after calcium IV infusion in high-risk women undergoing ART

Detailed Description

Among assisted reproductive technologies (ART), ovarian hyperstimulation syndrome (OHSS) is a serious iatrogenic complication affects up to 30% of women undergoing ART and caries high risks of morbidity and mortality. Women with age younger than 35 years, those with history of polycystic ovary syndrome (PCOS), or having a history of previous OHSS are more susceptible to develop OHSS

Eligibility

Age

18 - 45 years

Sex

FEMALE

Healthy Volunteers

Inclusion Criteria

•\- infertile women aged 20 to 38 years. BMI ranged from 18 to 40. serum FSH within normal limits( 1-12IU /l) presented with ovarian response suggestive of being at risk of developing OHSS because of the presence of at least 15 follicles of 10 mm or greater on the day of hCG administration.

Exclusion Criteria

•endocrinopathies. a systemic disease. and Insulin-dependent diabetes Thyroid disease using any medication (e.g., insulin-sensitizing drugs and GnRH antagonists. patients need coasting for high risk of OHSS. patients need cycle cancellation. severe male infertility requiring testicular sperm extraction.

Key Dates

Start Date

March 1, 2022

Primary Completion Date

April 25, 2023

Completion Date

May 10, 2023

Last Updated

February 22, 2022

Enrollment

200

ESTIMATED participants

Conditions

Ovarian Hyperstimulation Syndrome

Interventions

Calcium intravenous infsuion

DRUG

0.9 % saline

DRUG

Association Between Live Birth Rate and Serum Progesterone During Hormonal Replacement Therapy

NCT05588635

Ovarian Hyperstimulation SyndromeFrozen-thawed Embryo Transfers

View study

COMPLETEDPHASE2

Management of Ovarian Hyperstimulation Syndrome as a State of Defective Mineralocorticoid Response

NCT04351126

Ovarian Hyperstimulation Syndrome

View study

Data Source & Attribution

This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.

ClinicalTrials.gov last update: February 22, 2022Data synced to Clareo: March 29, 2026

Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.

Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.

View ClinicalTrials.gov Terms and Conditions

Ovarian Hyperstimulation Syndrome Using Calcium Infusion

Inclusion Criteria

Exclusion Criteria

Association Between Live Birth Rate and Serum Progesterone During Hormonal Replacement Therapy

Management of Ovarian Hyperstimulation Syndrome as a State of Defective Mineralocorticoid Response

Gene Expression Profile After Gonadotropin Releasing Hormone (GnRH) Agonist Trigger of Oocyte Maturation

Endometrial Receptivity After GnRH Agonist Triggering

The Effect of a Dual Trigger on Intracytoplasmic Sperm Injection (ICSI) Reproductive Outcomes

Administration of Increased Dose of GnRH Antagonist for Coasting for Decreasing the Risk for Ovarian Hyperstimulation Syndrome( OHSS)